AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Oral anthrax and plague vaccine to be developed for U.S. Department of Defense.
2003 FEB 12 - (NewsRx.com & NewsRx.net) -- Avant Immunotherapeutics, Inc. (AVAN) has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using Avant's proprietary vaccine technologies.
Under the agreement, Avant may receive in excess of $8 million over a 2-year period, covering vaccine development through preclinical testing. Avant executed the subcontract with DynPort Vaccine Co. LLC (DVC), the prime contractor for the Defense Department's Joint Vaccine Acquisition Program (JVAP). Headquartered in Fort Detrick, MD, JVAP is the lead Defense Department organization for the development and purchase of vaccines for the U.S. military.
"This contract represents one of the first awards from a major U.S. Department of Defense (DoD) initiative to apply modern biotechnological innovations to the development of vaccines that can offer rapid, effective protection from multiple biological agents," said Una S. Ryan, PhD, president and chief executive officer of Avant. "Current vaccines against bacterial bioweapons like anthrax (Bacillus anthracis) and plague (Yersinia pestis) require a protracted dosing regimen or provide only limited protection, and each vaccine protects against only a single agent. The Defense Department is looking for new, improved generation vaccines that are effective, single-dose, and can protect against multiple agents. The choice of Avant to conduct this development program is an important recognition of the strength of Avant's vaccine and vector technologies for accomplishing these aims."
DVC is currently developing seven vaccines for the Department of Defense Joint Vaccine Acquisition Program and is the first company to initiate clinical trials on the new smallpox vaccine for the Department of Defense. It is also expected to be the first to complete the trials for vaccine immune globulin (VIG), an antiserum needed for the smallpox vaccination program.
Under the subcontract, Avant will develop a rapid-acting oral anthrax and plague vaccine based on the company's modified live vaccine technology. This technology will use ...
- AVANT to Develop an Oral Anthrax and Plague Vaccine for U.S. Department of...
- Press release article from: Business Wire January 22, 2003 700+ words
...testing. AVANT executed the...contractor for the Defense Department's Joint...agent. The Defense Department is looking...choice of AVANT to conduct...pleased that the Defense Department has chosen AVANT, a leading...
- AVANT Achieves Milestones in Development of Injectable Anthrax and Oral...
- Press release article from: Business Wire June 5, 2003 700+ words
...vaccine constructs being developed by AVANT for an oral combination vaccine...prime systems contractor for the Defense Department's Joint Vaccine Acquisition Program...and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "The...
- AVANT Receives Additional Defense Contract for Clinical Testing of Plague...
- Press release article from: Business Wire April 21, 2004 700+ words
...vaccine candidate being developed by AVANT for use in an oral combination...prime systems contractor for the Defense Department's Joint Vaccine Acquisition Program...and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "We...
- Fiscal 2004 Defense Appropriations Bill Dedicates $3 Million to Ongoing...
- Press release article from: Business Wire September 29, 2003 700+ words
...Pilot Manufacturing AVANT Immunotherapeutics...0 million for the Defense Department's continued development...being carried out by AVANT Immunotherapeutics...funding to support the AVANT/Megan Health of Overland...currently used by the Defense Department. It will help ...
- Fiscal 2005 Defense Appropriations Bill Dedicates $2.8 Million to Ongoing...
- Press release article from: Business Wire July 26, 2004 700+ words
NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc...provides $2.8 million for the Defense Department's continued development of...project being carried out by AVANT. The dedicated funding supports...technology vaccine begun by AVANT in January 2003. AVANT expects...
- Fiscal 2007 Defense Appropriations Bill Dedicates $2.6 Million to Ongoing...
- Press release article from: Business Wire October 2, 2006 700+ words
NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc...provides $2.6 million for the Defense Department's continued development of...project being carried out by AVANT. The dedicated funding supports...technology vaccine begun by AVANT in January 2003. This financial...
- Avant to develop an oral anthrax and plague vaccine for US Department of...
- News wire article from: Asia Africa Intelligence Wire January 22, 2003 700+ words
...against anthrax and plague using Avant's proprietary vaccine technologies. Under the agreement, Avant may receive in excess of...through pre-clinical testing. Avant executed the subcontract with...the prime contractor for the Defense Department's Joint Vaccine Acquisition...
- Fiscal 2005 Defense Appropriations Bill dedicates $2.8 M to ongoing development...
- News wire article from: Asia Africa Intelligence Wire July 26, 2004 700+ words
...NewsBase - Press Release) Avant Immunotherapeutics Inc announced...provides $2.8 M for the Defense Department's continued development of...project being carried out by Avant Immunotherapeutics. The dedicated...technology vaccine begun by Avant Immunotherapeutics during Jan...
- Avant lifted by $8M US govt contract.
- Newspaper article from: Pharma Marketletter January 27, 2003 700+ words
Shares in Avant Immunotherapeutics...contract with the US Defense Department to develop an oral...The deal calls for Avant to develop a rapid...contractor for the Defense Department's Joint Vaccine Acquisition...page 20). Una Ryan, Avant's chief executive...
- AVANT CEO -- Dr. Una Ryan; Search For Better Plague, Smallpox Vaccines, CNNfn.
- News wire article from: The America's Intelligence Wire January 23, 2003 700+ words
...our next guest very timely. AVANT Immunotherapeutics has won...Ryan the president and CEO of AVANT and joins us from Boston...RYAN, PRES. & CEO, AVANT IMMUNOTHERAPEUTICS: Good morning...be doing more work with the Defense Department here? Will this be the primary...
Source: HighBeam Research, Oral anthrax and plague vaccine to be developed for U.S. Department...